Felix Müller
Project Leader in Clinical Research at University of Basel
Data updated
Research Footprint
Felix Müller appears in 26 tracked papers (2016–2026), most studied alongside LSD, MDMA and Psilocybin, across Healthy Volunteers, Anxiety Disorders and Neuroimaging & Brain Measures.
Most-cited paper: Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study (285 citations).
Frequent co-authors: Matthias Liechti, Stefan Borgwardt and Friederike Holze.
Publication Landscape
How the 26 papers Blossom tracks for Felix Müller line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Felix Müller's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 26 of 26 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Felix Müller publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Felix Müller publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Dr. Felix Müller is a senior physician and researcher specializing in psychedelic-assisted therapy. His work at the University of Basel focuses on the efficacy of LSD and MDMA for a range of psychiatric conditions. He explores the potential of these substances to induce long-lasting antidepressant effects and investigates the neurobiological underpinnings of their therapeutic action.
Key Impact
Conducting trials on the therapeutic potential of LSD for anxiety, depression, and alcohol dependence.
Collaboration Network
53 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Felix Müller's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Felix Müller is associated with.